

Overland Pharma Joint Venture with Allogene Therapeutics

Client News December 15, 2020

Gunderson Dettmer represented client Overland Pharma in its joint venture with Allogene Therapeutics forming new company, Allogene Overland Biopharm, a separate venture that will develop, manufacture and commercialize allogeneic CAR T (AlloCAR T™) therapies for patients with cancer in greater China, Taiwan, South Korea and Singapore.

In the announcement of the transaction, co-founder and chief medical officer of Overland Pharmaceuticals Hua Mu said, "Combined with Allogene's domain expertise, this positions Allogene Overland Biopharm to bring these important new therapies to patients and physicians fighting cancer across Asia and around the world."

The Gunderson deal team was led by Tim Ehrlich and included Peter Schoch, Stephen Wheeler and Kelvin Chan.

Related People



Timothy H. Ehrlich PARTNER P +1 617 648 9399



Stephen M. Wheeler OF COUNSEL P +1 617 648 9165



Kelvin W. Chan ASSOCIATE P +1 617 648 9333

Featured Insights

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Brazilian Carbon Capture Company Mornbak Announces asolvi Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California Al Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in "Where the legal battle stands around copyright and AI training"

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding